Literature DB >> 22780844

Antiangiogenic therapeutic approaches in multiple myeloma.

Domenico Ribatti1, Giuseppe Mangialardi, Angelo Vacca.   

Abstract

Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. The pathophysiology of MM-induced angiogenesis involves both direct production of angiogenic cytokines by plasma cells and their induction within the bone marrow microenvironment. An improved understanding of the importance of angiogenesis-related signaling in MM has allowed for the rational use of antiangiogenic therapies in this tumor. This review article summarizes the literature data concerning the employment of the most important antiangiogenic therapeutic agents actually used in preclinical models and clinical settings for the treatment of MM.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22780844     DOI： 10.2174/156800912802429346

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN： 1568-0096            Impact factor:   3.428


  7 in total

1.  Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.

Authors:  Chris Mahony; Lynda Erskine; Jennifer Niven; Nigel H Greig; William Douglas Figg; Neil Vargesson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

Review 2.  Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.

Authors:  Michele Moschetta; Yawara Kawano; Antonio Sacco; Angelo Belotti; Rossella Ribolla; Marco Chiarini; Viviana Giustini; Diego Bertoli; Alessandra Sottini; Monica Valotti; Claudia Ghidini; Federico Serana; Michele Malagola; Luisa Imberti; Domenico Russo; Alessandro Montanelli; Giuseppe Rossi; Michaela R Reagan; Patricia Maiso; Bruno Paiva; Irene M Ghobrial; Aldo M Roccaro
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

3.  CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.

Authors:  Abdel Kareem Azab; Ilyas Sahin; Michele Moschetta; Yuji Mishima; Nicholas Burwick; Johann Zimmermann; Barbara Romagnoli; Kalpana Patel; Eric Chevalier; Aldo M Roccaro; Irene M Ghobria
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

Review 4.  Autophagy in blood cancers: biological role and therapeutic implications.

Authors:  Alessio Nencioni; Michele Cea; Fabrizio Montecucco; Valter D Longo; Franco Patrone; Angelo M Carella; Tessa L Holyoake; G Vignir Helgason
Journal:  Haematologica       Date:  2013-09       Impact factor: 9.941

5.  Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.

Authors:  Lavinia Raimondi; Nicola Amodio; Maria Teresa Di Martino; Emanuela Altomare; Marzia Leotta; Daniele Caracciolo; Annamaria Gullà; Antonino Neri; Simona Taverna; Patrizia D'Aquila; Riccardo Alessandro; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Oncotarget       Date:  2014-05-30

Review 6.  MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment.

Authors:  Lavinia Raimondi; Angela De Luca; Eugenio Morelli; Gianluca Giavaresi; Pierosandro Tagliaferri; Pierfrancesco Tassone; Nicola Amodio
Journal:  Biomed Res Int       Date:  2016-01-04       Impact factor: 3.411

7.  High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma.

Authors:  Normann Steiner; Roman Hajek; Sabina Sevcikova; Bojana Borjan; Karin Jöhrer; Georg Göbel; Gerold Untergasser; Eberhard Gunsilius
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.